Manjiree Karandikar, MD

Education
12/2020 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 06/2018 - Pediatric Infectious Disease, Boston Children's Hospital
Certificate, 05/2018 - Advanced Training in Clinical and Translational Research, Clinical / Translational Research Academy, Harvard Catalyst
Residency, 06/2015 - Pediatrics, Harbor UCLA Medical Center
MD, 05/2012 - Medicine, Wayne State University School of Medicine
MBS, 05/2007 - Biopharmaceutical Drug Discovery and Development, Keck Graduate Institute
Honors and Awards
  • Haile T. Debas Academy of Medical Educators Excellence in Teaching Award, UCSF School of Medicine, 2021

  1. Karandikar MV, Coffin SE, Priebe GP, Sandora TJ, Logan LK, Larsen GY, Toltzis P, Gray JE, Klompas M, Sammons JS, Harper MB, Horan K, Lakoma M, Cocoros NM, Lee GM. Variability in antimicrobial use in pediatric ventilator-associated events. Infection control and hospital epidemiology 2018. PMID: 30409233


  2. Chiotos K, Tamma PD, Flett KB, Karandikar MV, Nemati K, Bilker WB, Zaoutis T, Han JH. Increased 30-Day Mortality Associated With Carbapenem-Resistant Enterobacteriaceae in Children. Open forum infectious diseases 2018. PMID: 30338267


  3. Dixit A, Karandikar MV, Jones S, Nakamura MM. Safety and Tolerability of Moxifloxacin in Children. Journal of the Pediatric Infectious Diseases Society 2018. PMID: 29939314


  4. Chiotos K, Tamma PD, Flett KB, Naumann M, Karandikar MV, Bilker WB, Zaoutis T, Han JH. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children. Antimicrobial agents and chemotherapy 2017. PMID: 28971864